中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

37 records (took 0.03 seconds)

    P27 and P21 in gene therapies
    1.
    发明授权
    P27 and P21 in gene therapies 有权
    P27和P21基因治疗

    公开(公告)号：US08088622B2

    公开(公告)日：2012-01-03

    申请号：US12331117

    申请日：2008-12-09

    Applicant: David T. Scadden ,  Tao Cheng

    Inventor： David T. Scadden ,  Tao Cheng

    IPC: C12N15/87

    CPC classification number: C12N5/0647 ,  A01K2217/05 ,  A61K48/00 ,  A61K2035/124 ,  C07K2319/00 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/23 ,  C12N2501/26 ,  C12N2501/405

    Abstract: The expansion of a population of stem cells or progenitor cells, or precursors thereof, may be accomplished by disrupting or inhibiting p21cip1/waf1 and/or p27, cyclin dependent kinase inhibitors. In the absence of p27 activity, progenitor cells move into the cell cycle and proliferate; whereas in the absence of p21 activity, stem cells move into the cell cycle and proliferate without losing their pluripotentiality (i.e., their ability to differentiate into the various cell lines found in the blood stream). Any type of stem cell or progenitor cell, or precursor thereof, including, but not limited to, hematopoietic, gastrointestinal, lung, neural, skin, muscle, cardiac muscle, renal, mesenchymal, embryonic, fetal, or liver cell may be used in accordance with the invention. The present invention provides a method of expanding a cell population, cells with decreased p27 and/or p21 activity, transgenic animals with a disrupted p27 and/or p21 gene, pharmaceutical compositions comprising the cells of the invention, and methods of using these cells in gene therapy (e.g., stem cell gene therapy) and bone marrow transplantation.

    Abstract translation: 干细胞或祖细胞群或其前体的扩增可以通过破坏或抑制p21cip1 / waf1和/或p27细胞周期蛋白依赖性激酶抑制剂来实现。 在没有p27活性的情况下，祖细胞进入细胞周期并增殖; 而在没有p21活性的情况下，干细胞进入细胞周期并增殖而不丧失其多能性（即，它们分化成血液中发现的各种细胞系的能力）。 包括但不限于造血，胃肠，肺，神经，皮肤，肌肉，心肌，肾，间充质，胚胎，胎儿或肝细胞的任何类型的干细胞或祖细胞或其前体可用于 根据本发明。 本发明提供了扩增细胞群的方法，具有降低的p27和/或p21活性的细胞，具有破坏的p27和/或p21基因的转基因动物，包含本发明细胞的药物组合物，以及使用这些细胞的方法 基因治疗（如干细胞基因治疗）和骨髓移植。

    Method of selecting pluripotent hematopioetic progenitor cells
    5.
    发明授权
    Method of selecting pluripotent hematopioetic progenitor cells 失效
    选择多能造血祖细胞的方法

    公开(公告)号：US5827742A

    公开(公告)日：1998-10-27

    申请号：US299902

    申请日：1994-09-01

    Applicant: David T. Scadden

    Inventor： David T. Scadden

    IPC: C12N5/0789 ,  C12N15/06 ,  G01N33/50

    CPC classification number: G01N33/5073 ,  C12N5/0647 ,  G01N33/5008

    Abstract: Methods of selecting a population of human cells containing quiescent pluripotent hematopoietic progenitor cells substantially free of mature, human myeloid and lymphoid cells, the quiescent pluripotent progenitor cells obtained by these methods, and methods of using the pluripotent progenitor cells are described.

    Abstract translation: 描述了选择含有基本上不含成熟的人类骨髓和淋巴细胞的静止多能造血祖细胞的人类细胞群，通过这些方法获得的静止多能祖细胞的方法和使用多能祖细胞的方法。

    CAR RECEPTOR AS A MEDIATOR OF MIGRATORY CELL CHEMOTAXIS AND/OR CHEMOKINESIS
    7.
    发明申请
    CAR RECEPTOR AS A MEDIATOR OF MIGRATORY CELL CHEMOTAXIS AND/OR CHEMOKINESIS 审中-公开
    CAR受体作为转染细胞化学和/或化学反应的介质

    公开(公告)号：US20120329153A1

    公开(公告)日：2012-12-27

    申请号：US13118511

    申请日：2011-05-30

    Applicant: Mark C. Poznansky ,  Edward M. Brown ,  David T. Scadden ,  Ivona T. Olszak

    Inventor： Mark C. Poznansky ,  Edward M. Brown ,  David T. Scadden ,  Ivona T. Olszak

    IPC: C12N5/0789 ,  C12N5/077

    CPC classification number: A61L27/3821 ,  A61K31/00 ,  A61K31/137 ,  A61K31/138 ,  A61K31/59 ,  A61K38/195 ,  A61K38/2006 ,  A61K45/06 ,  A61L27/3804 ,  A61L27/3847 ,  A61K2300/00

    Abstract: This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of CaR receptor expressing cells of hematopoietic, neural, epithelial, endothelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. Specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. The invention also relates to methods for manipulating io hematopoeitic progenitor cells and related products. In particular the invention includes methods and products for using CaR receptor-related compositions to enhance mobilization of hematopoietic progenitor cells, to improve the efficiency of targeting cells to the bone marrow, and/or to modulate hematopoietic progenitor cell function.

    Abstract translation: 本发明涉及用迁移能力调节真核细胞运动的方法和组合物。 更具体地，本发明涉及用于调节受试者的特定部位中造血，神经，上皮，内皮或间质来源的CaR受体表达细胞的运动的方法和组合物。 前述内容尤其可用于治疗特征在于需要调节与受试者中特定部位相关的迁移细胞运动的病症。 特定部位包括炎症部位和迁移细胞运动的调节是远离药剂来源或排斥的运动。 本发明还涉及用于操作io血型祖细胞和相关产品的方法。 特别地，本发明包括使用CaR受体相关组合物来增强造血祖细胞的动员，提高靶向细胞到骨髓的效率和/或调节造血祖细胞功能的方法和产品。

    CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
    9.
    发明授权
    CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis 有权
    CaR受体作为迁移性细胞趋化性和/或趋化因子的介质

    公开(公告)号：US07951364B2

    公开(公告)日：2011-05-31

    申请号：US11429902

    申请日：2006-05-08

    Applicant: Mark C. Poznansky ,  Edward M. Brown ,  David T. Scadden ,  Ivona T. Olszak

    Inventor： Mark C. Poznansky ,  Edward M. Brown ,  David T. Scadden ,  Ivona T. Olszak

    IPC: A01N63/00

    CPC classification number: A61L27/3821 ,  A61K31/00 ,  A61K31/137 ,  A61K31/138 ,  A61K31/59 ,  A61K38/195 ,  A61K38/2006 ,  A61K45/06 ,  A61L27/3804 ,  A61L27/3847 ,  A61K2300/00

    Abstract: This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of CaR receptor expressing cells of hematopoietic, neural, epithelial, endothelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. Specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. The invention also relates to methods for manipulating hematopoeitic progenitor cells and related products. In particular the invention includes methods and products for using CaR receptor-related compositions to enhance mobilization of hematopoietic progenitor cells, to improve the efficiency of targeting cells to the bone marrow, and/or to modulate hematopoietic progenitor cell function.

    Abstract translation: 本发明涉及用迁移能力调节真核细胞运动的方法和组合物。 更具体地，本发明涉及用于调节受试者的特定部位中造血，神经，上皮，内皮或间质来源的CaR受体表达细胞的运动的方法和组合物。 前述内容尤其可用于治疗特征在于需要调节与受试者中特定部位相关的迁移细胞运动的病症。 特定部位包括炎症部位和迁移细胞运动的调节是远离药剂来源或排斥的运动。 本发明还涉及操纵造血祖细胞和相关产品的方法。 特别地，本发明包括使用CaR受体相关组合物来增强造血祖细胞的动员，提高靶向细胞到骨髓的效率和/或调节造血祖细胞功能的方法和产品。

Patent Agency Ranking